NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-250-2005-0-EP-43 METHODS FOR TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS EP DIV 11182581.6 Abandoned
NIAID E-250-2005-0-JP-37 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis JP National Stage 2008-506683 Pending
NIAID E-250-2005-0-TW-08 Methods for Treating and Preventing Fibrosis TW National Stage 95113160 Pending
NIAID E-250-2005-0-EP-33 METHODS FOR TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS EP National Stage 06750009.0 Pending
NIAID E-250-2005-0-CN-40 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis CN National Stage 200680021090.6 Pending
NIAID E-250-2005-0-PH-38 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis PH National Stage 1-2007-502249 Pending
NCI E-029-2005-0-ZA-08 Combination Approaches for Generating Immune Responses ZA National Stage 2006/03029 Expired
NIAID E-250-2005-0-RU-18 METHODS FOR TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS RU National Stage 2007138011 Pending
NIAID E-250-2005-0-PK-15 METHODS FOR TREATING AND PREVENTING FIBROSIS PK National Stage 343/2006 Abandoned
NIAID E-250-2005-0-NO-39 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis NO National Stage 2007 5193 Pending
NIAID E-250-2005-0-KR-29 METHODS FOR TREATING AND PREVENTING FIBROSIS KR National Stage 2007-7026544 Pending
NIAID E-250-2005-0-SG-42 METHODS FOR TREATING AND PREVENTING FIBROSIS BY IL-21 I IL-21R ANTAGONISTS SG DIV 201002668-0 Pending
NIAID E-250-2005-0-SG-27 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis SG National Stage 200716993-1 Abandoned
NIAID E-250-2005-0-NI-25 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis NI National Stage 2007/0259 Abandoned
NIAID E-250-2005-0-EG-21 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis EG National Stage PCT/NA/1085/2007 Abandoned
NIAID E-250-2005-0-CR-28 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis CR National Stage 9428-11-09 Abandoned
NIAID E-250-2005-0-EC-36 METHODS FOR TREATING AND PREVENTING FIBROSIS EC ORD SP-07-7821 Abandoned
NIAID E-250-2005-0-CO-31 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis CO National Stage 07.108.813 Pending
NIAID E-250-2005-0-SV-06 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis SV National Stage 2479-06-09 Abandoned
NIAID E-250-2005-0-CL-11 METHODS FOR TREATING AND PREVENTING FIBROSIS CL National Stage 857/2006 Abandoned
NIAID E-250-2005-0-CA-23 METHODS FOR TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS CA National Stage 2604604 Abandoned
NIAID E-250-2005-0-UA-24 METHOD FOR TREATING AND PREVENTING FIBROSIS UA National Stage 200711402 Abandoned
NIAID E-250-2005-0-IN-34 METHODS FOR TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS IN National Stage 7772/DELNP/2007 Pending
NIAID E-250-2005-0-ID-22 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis ID National Stage W-00200703394 Pending
NIAID E-250-2005-0-HN-13 METHODS FOR TREATING AND PREVENTING FIBROSIS HN National Stage 2006-14.635 Pending
NIAID E-250-2005-0-IL-19 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis IL National Stage 186599 Pending
NIAID E-250-2005-0-MY-12 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis MY National Stage PI20061695 Pending
NIAID E-250-2005-0-MX-30 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis MX National Stage MX/A/2007/012842 Pending
NCI E-080-2006-0-US-01 Tetrahalogenated Compounds Useful as Inhibitors US 60/792,098 Abandoned
NIAID E-250-2005-0-VN-35 A PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS VN National Stage 1-2007-02418 Abandoned
NIAID E-167-2006-0-US-01 Synergistic Benefit From The Treatment Of A Porphyrin And Pentosan Polysulfate Against Scrapie US 60/791,451 Abandoned
NIAID E-250-2005-0-AU-32 METHODS FOR TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS AU National Stage 2006236755 Abandoned
NIAID E-250-2005-0-BR-20 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis BR National Stage PI0609762-6 Pending
NIAID E-250-2005-0-PA-10 METHODS FOR TREATING AND PREVENTING FIBROSIS PA National Stage 86688-01 Abandoned
NCI E-296-2004-0-US-02 Novel Forms Of Interleukin-15, Fc-IL-15, For Various Immunotherapies US ORD 11/403,681 Abandoned
NIAID E-250-2005-0-TH-07 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammation And Tissue Fibrosis TH National Stage 0601001717 Abandoned
NIAID E-250-2005-0-VE-09 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis VE National Stage 2006-00823 Pending
NIAID E-250-2005-0-AR-04 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammation And Tissue Fibrosis AR National Stage P060101469 Pending
NCI E-155-2005-3-EP-03 METHODS AND COMPOSITIONS FOR PRODUCING AN ENHANCED IMMUNE RESPONSE TO A HUMAN PAPILLOMAVIRUS IMMUNOGEN EP National Stage 06749659.6 Abandoned
NCI E-155-2005-3-AU-04 T-cell Binding Epitope From The Human Papillomaviurs Type 16 E2 Region That Induces Significan CD8+ Cell Response And CTL Lysis Activity Both Bound To HLA.A2 And When Pulsed As A Peptide. AU National Stage 2006236905 Abandoned
NCI E-155-2005-3-PCT-01 METHODS OF COMPOSITIONS FOR PRODUCING AN ENHANCED IMMUNE RESPONSE TO A HUMAN PAPILLOMAVIRUS IMMUNOGEN PCT PCT COMB PCT/US2006/013315 Expired
NCI E-348-2004-0-PCT-02 THYMIDINE DERIVATIVES FOR THE TREATMENT OF KAPOSI'S SARCOMA PCT PCT PCT/US2006/013272 Expired
NCI E-155-2005-3-CA-05 Methods and Compositions For Producing An Enhanced Immune Response To A Human Papilloma Virus Immunogen CA National Stage 2604909 Abandoned
NIDCR E-229-2004-0-US-03 Mammalian T1R3 Sweet Taste Receptors US DIV 11/402,202 7459277 Expired PDF
NIAID E-250-2005-0-GT-14 METHODS FOR TREATING AND PREVENTING FIBROSIS GT National Stage PI-2006-0148 Abandoned
NCI E-128-2005-0-EP-05 RAPID GENERATION OF LONG SYNTHETIC CENTROMERIC TANDEM REPEATS FOR MAMMALIAN ARTIFICIAL CHROMOSOME FORMATION. EP National Stage 06749677.8 Abandoned
NCI E-128-2005-0-AU-03 RAPID GENERATION OF LONG SYNTHETIC CENTROMERIC TANDEM REPEATS FOR MAMMALIAN ARTIFICIAL CHROMOSOME FORMATION. AU National Stage 2006235356 Abandoned
NCI E-128-2005-0-PCT-02 RAPID GENERATION OF LONG SYNTHETIC CENTROMERIC TANDEM REPEATS FOR MAMMALIAN ARTIFICIAL CHROMOSOME FORMATION. PCT PCT PCT/US2006/013362 Expired
NCI E-128-2005-0-CA-04 RAPID GENERATION OF LONG SYNTHETIC CENTROMERIC TANDEM REPEATS FOR MAMMALIAN ARTIFICIAL CHROMOSOME FORMATION. CA National Stage 2616085 Abandoned
NIA E-251-1997-0-US-09 Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof US CON 11/400,715 Abandoned